Sunday September 7, 2014

16:15  Opening Ceremony

16:35  Portugal: the Right Place to build Partnerships in Health
Dr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)

16:50  Partnership between Public and Private Sources: Pharma and IMI Perspective
Dr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)

17:10  EFMC Award Ceremony

17:35  The Nauta Award for Pharmacochemistry
Pursuing Compound Quality
Dr Paul LEESON
(GLAXOSHITHERKLINE, Nuneaton, United Kingdom)

18:20  High Resolution Mass Spectrometry in Clinical Proteomics
Prof. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)

19:10  Welcome Reception
Monday September 8, 2014

08:30  The UCB-Ehrlich Award for Excellence in Medicinal Chemistry  
Small Molecule Control Of Intracellular Protein Levels  
Prof. Craig CREWS  
(YALE UNIVERSITY, New Haven, CT, United States)

09:15  The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery  
Thermodynamics Assisted Drug Discovery  
Dr György G. FERENCZY (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)  
Prof. György KESERU (HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

10:00  Exhibition & Coffee

Session 1.1 Inflammation: the Common Link in Multifactorial Disorders?

10:30  Session Chair  
Prof. Angeliki KOUROUNAKIS  
(UNIVERSITY OF ATHENS, Athens, Greece)

10:35  Inflammation, Obesity and Metabolic Disease  
Dr Ajay CHAWLA  
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

11:15  CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis  
Dr Uwe GREther  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

11:35  The Discovery of APD334, a Selective S1P1 Functional Antagonist  
Dr Robert JONES  
(ARENA PHARM, SAN DIEGO, United States)

11:55  Discovery of Small Molecule Ror? Modulators for the Treatment of Autoimmune Diseases  
Dr Frank NARJES  
(_ASTRAZENECA, Gothenburg, Sweden)

Session 1.2 Computational Approaches To Guide Medicinal Chemistry

10:30  Session Chair  
Prof. Helmut GRUBMÜLLER  
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

10:35  Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function  
Prof. Helmut GRUBMÜLLER  
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

11:15  Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter  
Dr Chris CHIPOT  
(UNIVERSITY OF ILLINOIS, Urbana, United States)

11:35  Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?  
Dr Clara CHRIST  
(BAYER, Berlin, Germany)

11:55  P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies  
Mr Ricardo FERREIRA  
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

Session 1.3 Organic Synthesis that Changed Medicinal Chemistry

10:30  Session Chair  
Dr Morten JORGENSEN  
(H. LUNDBECK A/S, Valby, Denmark)

10:35  Recent Advances In Asymmetric Catalysis
Programme Schedule

11:15  New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids  
Prof. Pier Giorgio COZZI  
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

11:35  Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry  
Dr Marc MOSRIN  
(BAYER CROPSCIENCE AG, Frankfurt am Main, Germany)

11:55  Development of Novel Building Blocks to Accelerate Drug Discovery  
Dr Pavel MYKHAILIUK  
(ENAMINE, Kyiv, Ukraine)

12:15  Exhibition & Lunch

Session 2.4 Combating Antibiotic Resistance

13:15  Session Chair  
Prof. Ada YONATH  
(WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel)

Prof. Erik BOETTGER  
(UNIVERSITY OF ZURICH, Zürich, Switzerland)

14:00  Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target  
Prof. Stephen DOUTHWAITE  
(UNIVERSITY OF SOUTHERN DENMARK, Odense, Denmark)

14:20  The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design  
Dr Moran SHALEV-BENAMI  
(WEIZMANN INSTITUTE, Rehovot, Israel)

14:40  Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents  
Dr Martin EMPTING  
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

Session 2.5 Taming Natural Products: Novel Natural Products, Complex Synthesis, Mutasynthesis

13:15  Session Chair  
Prof. Anake KIJJOA  
(UNIVERSITY OF PORTO, Porto, Portugal)

13:20  Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development  
Dr Esther SCHMITT  
(NOVAARTIS, Basel, Switzerland)

14:00  Sponging Off Nature for New Drug Leads  
Prof. Raymond ANDERSEN  
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

14:20  Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya  
Prof. Anake KIJJOA  
(UNIVERSITY OF PORTO, Porto, Portugal)

14:40  From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein  
Dr Fanny ROUSSI  
(ICSN - CNRS, Gif sur Yvette, France)

Session 2.6 Mechanism-Based Prediction of Drug-Induced Liver Injury  
(Eufeps Session)

13:15  Session Chair  
Prof. Nico VERMEULEN  
(VU UNIVERSITY, Amsterdam, The Netherlands)

13:20  Mechanism-Based Prediction of Drug-Induced Liver Injury
Dr Christopher GOLDRING  
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)

14:00  Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites  
Prof. Nico VERMEULEN  
(VU UNIVERSITY, Amsterdam, The Netherlands)

14:20  Being More Certain About Uncertainty In Computational Toxicology Modeling  
Dr Scott BOYER  
(KAROLINSKA INSTITUTET, Barcelona, Spain)

14:40  Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?  
Dr Alexandra ANTUNES  
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)

15:00  Exhibition & Coffee

15:30  MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application  
Prof. Christian HEINIS  
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Session 3.7 EFMC Session

15:55  Session Chair  
Dr Phil JONES  
(UNIVERSITY OF DUNDEE, Glasgow, United Kingdom)

16:00  The Open Phacts Discovery Platform - Semantic Data Integration For Medicinal Chemists  
Prof. Gerhard ECKER  
(UNIVERSITY OF VIENNA, Vienna, Austria)

16:30  European Lead Factory - Game Changing For Innovative Medicines  
Dr Dimitrios TZALIS  
(TAROS CHEMICALS, Dortmund, Germany)

17:00  Funding Opportunities with the Innovative Medicines Initiative 2  
Dr Colm CARROLL  
(INNOVATIVE MEDICINES INITIATIVE, Brussels, Belgium)

17:30  Poster Session I and Networking

19:30  End of the day

20:30  Concert (free of charge, but subject to registration)
Tuesday September 9, 2014

08:30  Prize Ceremony

08:35  EFMC Prize for a Young Medicinal Chemist in Industry
Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC
Dr Grazia PIIZZI
(NOVARTIS PHARMA, Basel, Switzerland)

08:55  EFMC Prize for a Young Medicinal Chemist in Academia
Inhibitors and Substrates of the Human Lysine Deacylase Enzymes
Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

09:15  Plenary Lecture
Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

10:00  Exhibition & Coffee

Session 4.8 Applications of Positron Emission Tomography in Drug Discovery
(ACS Session I)

10:30  Session Chair
Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

10:35  PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery
Dr Peter J.H. SCOTT
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

11:15  A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development
Dr Chad ELMORE
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)

11:35  Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging
Dr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

Dr Stefanie KRAMER
(ETH ZÜRICH, Zürich, Switzerland)

Session 4.9 Decoding Disease: Liganding and Drugging Bromodomain Epigenetic Readers

10:30  Session Chair
Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

10:35  BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction
Prof. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

11:15  A First In Class Chemical Probe For Family VIII Bromodomains
Dr Dafydd OWEN
(PFIZER, Cambridge, United States)

11:35  Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins
Prof. Paul FISH
(UCL SCHOOL OF PHARMACY, London, United Kingdom)
11:55  Interrogation the Bromodomain Family through Chemical Biology  
Dr Steve BELLON  
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Session 4.10 Organic Synthesis: New Developments  
(EuChemS Session)

10:30  Session Chair  
Prof. Péter MÁTYUS  
(SEMMELWEIS UNIVERSITY, Budapest, Hungary)  
(THERMO FISHER SCIENTIFIC)

10:35  Experiences with Natural Product Total Synthesis  
Prof. Alois FÜRSTNER  
(MAX PLANCK INSTITUT FUR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

11:15  New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds  
Prof. Artur M.S. SILVA  
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)

11:35  Fast and Safe Synthesis of Pharmaceutically Relevant Molecules  
Prof. Thomas WIRTH  
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)

11:55  Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases  
Prof. Marko D. MIHOVILOVIC  
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)

12:15  Exhibition & Lunch

Session 5.11 Oncology: Kinases and Beyond

13:15  Session Chair  
Dr Mario VARASI  
(EUROPEAN INSTITUTE OF ONCOLOGY, Milano, Italy)

13:20  Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer  
Prof. Filippo MINUTOLO  
(UNIVERSITY OF PISA, Pisa, Italy)

14:00  Novel Anti-Cancer Treatment Targeting Vps34  
Dr Jessica MARTINSSON  
(SPRINT BIOSCIENCE, Stockholm, Sweden)

14:20  Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors  
Dr Maria Emilia DI FRANCESCO  
(UTMD ANDERSON CANCER CENTER, Houston, United States)

14:40  Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a  
Dr Michael MICHAELIDES  
(ABBVIE, North Chicago, United States)

Session 5.12 Recent Advances in Anti-infective Agents  
(AFMC Session)

13:15  Session Chair  
Dr Ming-Hua HSU  
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

13:20  Development of New Anti-Infective Agents and a Novel Delivery Strategy  
Prof. Reuben JIH-RU HWU  
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

14:00  Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds  
Prof. Han-Young KANG  
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)

14:20  Novel Boron-containing Anti-infective Agents
Dr Jacob PLATTNER  
(ANACOR PHARMACEUTICALS, Palo Alto, United States)  
14:40 Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists  
Prof. Marko ANDERLUH  
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)  

Session 5.13 New Strategies for Lead Generation  
13:15 Session Chair  
(THERMO FISHER SCIENTIFIC)  
13:20 Integration of New Chemical Diversity and Design Approaches in Lead Generation  
Dr Timothy GRESE  
(ELI LILLY AND COMPANY, Indianapolis, United States)  
14:00 The Impact of Polypharmacology on Lead Generation  
Prof. Jordi MESTRES  
(IMIM AND UNIVERSITY POMPEU FABRA, Girona, Spain)  
14:20 Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation  
Dr Steve WOODHEAD  
(TAKEDA CALIFORNIA, San Diego, United States)  
14:40 Discovery of the First and Only Small Molecule Il-17 Blockers  
Dr Nils HANSEN  
(VIPERGEN, Copenhagen, Denmark)  
15:00 Exhibition & Coffee  
15:30 Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery  
Prof. Chas BOUNTRA  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)  
16:30 Poster Session II and Networking  
18:30 End of the day
Wednesday September 10, 2014

08:30 IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D
Dr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)

09:15 Innovation Through Chemistry at the Interfaces of the Scientific Disciplines
Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)

10:00 Exhibition & Coffee

Session 6.14 New Chemical Entities: Beyond Small Molecules
10:30 Session Chair
Prof. Stan VAN BOECKEL
(LEIDEN INSTITUTE OF CHEMISTRY, Leiden, The Netherlands)

10:35 Cyclic Peptides from the nature to the synthetic ones
Prof. Fernando ALBERICIO
(INSTITUTE FOR RESEARCH IN BIOMEDICINE, Durban , South Africa)

11:15 Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics
Dr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)

11:35 Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells
Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)

11:55 Novel Inhibitors of Alzheimer’s Associated Beta-Secretase-Clusters of Heparan Sulfate
Dr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)

Session 6.15 Novel Agents for the Treatment of C. Difficile
(ACS Session II)
10:30 Session Chair
Prof. Steven FIRESTINE
(WAYNE STATE UNIVERSITY, Detroit, United States)

10:35 Discovery and Development of Surotomycin for the Treatment of C. difficile
Dr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)

11:15 Invited Lecture
Dr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)

11:35 Targeting Spore Germination to Prevent Clostridium Difficile Infections
Dr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)

11:55 Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Dr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

Session 6.16 Kinetic and Thermodynamic Aspects of Ligand Binding
10:30 Session Chair
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

10:35 Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors
### Programme Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 7.17 Recent Highlights in Medicinal Chemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15</td>
<td>Session Chair</td>
</tr>
<tr>
<td></td>
<td>Prof. Carlos MONTANARI</td>
</tr>
<tr>
<td></td>
<td>(UNIVERSITY OF SAO PAULO, Sao Paulo, Brazil)</td>
</tr>
<tr>
<td>13:20</td>
<td>Cebranopadol, a Novel, Potent Analgesic</td>
</tr>
<tr>
<td></td>
<td>Dr Henning STEINHAGEN</td>
</tr>
<tr>
<td></td>
<td>(GRÜNENTHAL, Verona, Italy)</td>
</tr>
<tr>
<td>13:40</td>
<td>Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies</td>
</tr>
<tr>
<td></td>
<td>Dr Wolfgang SCHWEDE</td>
</tr>
<tr>
<td></td>
<td>(BAYER, Berlin, Germany)</td>
</tr>
<tr>
<td>14:00</td>
<td>Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease</td>
</tr>
<tr>
<td></td>
<td>Dr Christopher LUCKHURST</td>
</tr>
<tr>
<td></td>
<td>(BIOFOCUS, Saffron Walden, United Kingdom)</td>
</tr>
<tr>
<td>14:20</td>
<td>Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Dr Erin DIMAURO</td>
</tr>
<tr>
<td></td>
<td>(AMGEN, Cambridge, United States)</td>
</tr>
<tr>
<td>14:40</td>
<td>Novel Potent Inhibitors of the Histone Demethylase KDM1A</td>
</tr>
<tr>
<td></td>
<td>Dr Paola VIANELLO</td>
</tr>
<tr>
<td></td>
<td>(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 7.18 Hot Topics in Ion Channels</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15</td>
<td>Session Chair</td>
</tr>
<tr>
<td></td>
<td>Prof. Brian COX</td>
</tr>
<tr>
<td></td>
<td>(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Brighton, United Kingdom)</td>
</tr>
<tr>
<td>13:20</td>
<td>An Introduction To Ion Channels As Drug Targets</td>
</tr>
<tr>
<td></td>
<td>Prof. Morten GRUNNET</td>
</tr>
<tr>
<td></td>
<td>(LUNDBECK, Valby, Germany)</td>
</tr>
<tr>
<td>14:00</td>
<td>CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study</td>
</tr>
<tr>
<td></td>
<td>Dr Gerard GIBLIN</td>
</tr>
<tr>
<td></td>
<td>(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)</td>
</tr>
<tr>
<td>14:20</td>
<td>Pain-relieving Peptides Targeting Acid-Sensing Ion Channels</td>
</tr>
<tr>
<td></td>
<td>Dr Eric LINGUEGLIA</td>
</tr>
<tr>
<td></td>
<td>(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)</td>
</tr>
<tr>
<td>14:40</td>
<td>Discovery of Ivacaftor (Vx-770), a Cfr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients</td>
</tr>
<tr>
<td></td>
<td>Dr Sabine HADIDA</td>
</tr>
<tr>
<td></td>
<td>(VERTEX PHARMACEUTICALS, San Diego, United States)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 7.19 Allosteric Modulators for CNS Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.</td>
</tr>
<tr>
<td></td>
<td>Prof. Iwan DE ESCH</td>
</tr>
<tr>
<td></td>
<td>(VRIJE UNIVERSITEIT AMSTERDAM, Amsterdam, The Netherlands)</td>
</tr>
<tr>
<td>11:35</td>
<td>Medicinal Chemistry Optimisation Of Binding Kinetics</td>
</tr>
<tr>
<td></td>
<td>Prof. Mike WARING</td>
</tr>
<tr>
<td></td>
<td>(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)</td>
</tr>
<tr>
<td>11:55</td>
<td>CRTH2: Can Residence Time Help?</td>
</tr>
<tr>
<td></td>
<td>Dr Elena GOMEZ</td>
</tr>
<tr>
<td></td>
<td>(ALMIRALL, BARCELONA, Spain)</td>
</tr>
<tr>
<td>12:15</td>
<td>Exhibition &amp; Lunch</td>
</tr>
</tbody>
</table>
13:15  Session Chair  
Dr Wolfgang FROESTL  
(AC IMMUNE, Lausanne, Switzerland)

13:20  Functional and Structural Insights into GPCR Allostery  
Prof. Arthur CHRISTOPOULOS  
(MONASH UNIVERSITY, Parkville, Australia)

14:00  Discovery of the mGlu5 Negative Allosteric Modulator RO4917523  
Dr Georg JAESCHKE  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

14:20  Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies  
Prof. Ana MARTINEZ  
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

14:40  Antibodies as Tools to Enable Small Molecule Drug Discovery  
Dr Marta WESTWOOD  
(UCB, Slough, United Kingdom)

15:00  Excursions

20:00  Banquet
Thursday September 11, 2014

Session 8.20 GPCR Structural Biology: New Therapeutic Opportunities?

08:30  Session Chair
       Prof. Jan STEYAERT
              (VUB, Brussels, Belgium)

08:35  High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies
       Dr. Jonathan MASON
              (HEPTARES THERAPEUTICS, Cambridge, United Kingdom)

09:15  Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs
       Prof. Jan STEYAERT
              (VUB, Brussels, Belgium)

09:35  Covalent Agonists Facilitating Crystallisation of GPCRs
       Prof. Peter GMEINER
              (FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

09:55  Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening
       Dr David RODRIGUEZ DIAZ
              (STOCKHOLM UNIVERSITY, Solna, Sweden)

Session 8.21 Neglected Tropical Diseases: Shaping Future Trends

08:30  Session Chair
       Prof. Kelly CHIBALE
              (UNIVERSITY OF CAPE TOWN, Cape Town, South Africa)

08:35  Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites
       Prof. Reto BRUN
              (SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

09:15  Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery
       Dr Adam RENSLO
              (UNIVERSITY OF CALIFORNIA, San Francisco, United States)

09:35  Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box
       Dr Francisco-Javier GAMO
              (GLAXOSMITHKLINE, Madrid, Spain)

09:55  Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei
       Prof. Jennifer WOODRING
              (NORTHEASTERN UNIVERSITY, Boston, United States)

Session 8.22 New Therapies for Metabolic Disorders

08:30  Session Chair
       Dr Jürgen MACK
              (BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

08:35  Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing
       Dr Jesper LAU
              (NOVO NORDISK, Maaloev, Denmark)

09:15  1,1'-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors
       Dr Thomas TRIESELMANN
              (BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

09:35  Omarigliptin: A Once-weekly Oral Antidiabetic Agent
       Dr Tesfaye BIFTU
              (MERCK, Rahway, United States)

09:55  Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism
       Dr Anneli NORDQVIST
              (ASTRAZENECA, BIOPHARMACEUTICALS R&D, Gothenburg, Sweden)
10:15   Exhibition & Coffee & Snacks

Session 9.23 Late Breaking News

10:45  Session Chair
Dr Laurence LAFANECHERE
(CNRS, Grenoble, France)

10:50  CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization
Dr Maurizio DELCANALE
(CHIESI, Parma, Italy)

11:10  The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma
Dr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)

11:30  Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases
Dr Franz VON NUSSBAUM
(BAYER PHARMA, Berlin, Germany)

11:50  Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD
Dr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)

12:10  Identifying Selective Inhibitors of FGFR4 Kinase
Dr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

Session 9.24 Neurodegeneration: Deeper Understanding of Disease Biology and Emerging Therapeutic Options

10:45  Session Chair
Dr Andrew THOMAS
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

10:50  CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson’s Disease
Prof. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)

11:30  Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect
Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

11:50  Fragment-Based Discovery of BACE Inhibitors for Alzheimer’s Disease
Dr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)

12:10  The Evolution of an in vivo Efficacious Bace1 Inhibitor
Dr Daniel OEHLRICH
(JANSSEN RESEARCH AND DEVELOPMENT, Beerse, Belgium)

Session 9.25 Translational Medicine: Case Studies with Biomarkers and PKPD Modeling

10:45  Session Chair
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

10:50  Translational Modeling in Support to Discovery and Early Development
Dr Thierry LAVE
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

11:30  Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721
Dr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)

11:50  A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement
Mr Alban BUJARD  
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

12:10 Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer  
Dr Martyna KRZYKAWSKA-SERDA  
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

12:30 Closing Lecture  
Personalised Medicinal Systems Chemistry  
Prof. Hans WESTERHOFF  
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

13:15 Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2016